Zydus Lifesciences shares rose nearly 2% to Rs 899.40 after receiving USFDA approval to manufacture Eluxadoline Tablets (75 ...

Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) ...

Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last ...

The uptick in the Zydus Life shares came after the company received final approval from the USFDA to manufacture Eluxadoline ...

Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive ...

Indian equity indices ended strong on Friday, with the NIFTY closing at 23,350.40, up 159.75 points (0.69%), while the Sensex ...

On Monday, 1608 stocks advanced, 2503 declined and 130 remained unchanged on Bombay Stock Exchange with advance decline ratio ...

The NSE Nifty 50 ended 0.33% lower at 22,397.20, while the BSE Sensex closed 0.27% down at 73,828.9 on Thursday.

This is driven by a surge in the prices of manufacturing of food products, food articles, non-food articles, and textiles, among others, reports The Economic Times.

Zydus Lifesciences shares surged nearly 2% to Rs 899.40 on the BSE on Monday after the company received final approval from ...

2. Zydus Life: Received USFDA approval for Eluxadoline Tablets with 180 days of exclusivity, targeting a $243.7 million market. 3. Maharashtra Seamless: Secured a ₹298 crore order for seamless ...